Showing results (51-60 of 91) with videos related to
Sort By:
Pageof 10
Neoplasia (New York, N.Y.)|May 13, 2017
Control of Tumor Initiation by NKG2D Naturally Expressed on Ovarian Cancer CellsXin Cai, Andrea Caballero-Benitez, Mesfin M Gewe, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 11, 2012
Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancerNicole Urban, Jason Thorpe, Beth Y Karlan, et al.American Journal of Obstetrics and Gynecology|March 18, 2011
Surgical outcomes in gynecologic oncology in the era of robotics: analysis of first 1000 casesPamela J Paley, Dan S Veljovich, Chirag A Shah, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancerVivian Goodell, Lupe G Salazar, Nicole Urban, et al.Nucleic Acids Research|September 19, 2015
Targeted single molecule mutation detection with massively parallel sequencingMark T Gregory, Jessica A Bertout, Nolan G Ericson, et al.International Journal of Health Geographics|September 6, 2007
Participatory mapping of target areas to enable operational larval source management to suppress malaria vector mosquitoes in Dar es Salaam, TanzaniaStefan Dongus, Dickson Nyika, Khadija Kannady, et al.Plos Biology|September 28, 2011
ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinomaJulia Salzman, Robert J Marinelli, Peter L Wang, et al.Cancer|December 13, 2006
Development of an ovarian cancer symptom index: possibilities for earlier detectionBarbara A Goff, Lynn S Mandel, Charles W Drescher, et al.Omics : a Journal of Integrative Biology|May 9, 2009
Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancersSheng Pan, Lihua Cheng, James T White, et al.Gynecologic Oncology|December 6, 2000
A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneumJ V Brown, W A Peters, M A Rettenmaier, et al.Pageof 10